Table 6.

Binary pharmacological activity analysis based on a plasma parent MT threshold of 0.346 ng/ml to define a proxy for placebo; modelled difference in change from baseline for the respective endpoints

		All patients					Patients receiving hydromethylthionine 8 mg/day
	Decline±SEM for Cmax,ss ≤0.346 ng/ml	Difference±SEM for Cmax,ss > 0.346 ng/ml	CI	p	Nlow	Nhigh	Difference±SEM for Cmax,ss > 0.346 ng/ml	CI	p	Nlow	Nhigh
ACE-R	–11.33 ± 2.09	1.37±2.60	–3.73, 6.47	0.5973	30	130	5.06±2.62	–0.08, 10.21	0.0536	30	60
FAQ	7.13 ± 1.06	–2.98±1.10	–5.15, –0.82	0.0069	30	129	–3.27±1.32	–5.85, –0.69	0.0131	30	60
WBV (cm3)	–27.72 ± 2.73	9.05±3.06	3.06, 15.04	0.0031	28	115	11.67±3.41	5.00, 18.36	0.0006	28	52
LVV (cm3)	9.13 ± 0.82	–3.41±–0.95	–5.27, –1.55	0.0003	28	107	–4.12±1.06	–6.19, –2.05	<0.0001	28	46
FTV (cm3)	–2.47 ± 0.22	0.73±0.24	0.26, 1.19	0.0023	28	115	0.72±0.27	0.19, 1.26	0.0076	28	52
FRS	–0.14 ± 0.03	0.04±0.03	–0.02, 0.10	0.1527	30	130	0.04±0.03	–0.03, 0.10	0.2519	30	60
CGIC	–1.34 ± 0.20	0.42±0.22	–0.02, 0.85	0.0623	30	130	0.64±0.27	0.12, 1.17	0.0157	30	60
MMSE	–2.95 ± 0.93	–0.43±1.05	–2.48, 1.62	0.6788	30	130	0.41±1.04	–1.64, 2.45	0.6974	29	58
ACE-III	–9.47 ± 2.40	1.27±2.73	–4.08, 6.61	0.6418	26	122	4.36±2.94	–1.40, 10.13	0.1380	29	58
UPDRS-part III	5.71 ± 1.85	–3.27±2.09	–7.37, 0.81	0.1163	29	123	–4.31±2.69	–9.58, 0.95	0.1085	31	62